Altamira Therapeutics announces market approval of Bentrio nasal spray in China

Altamira Therapeutics Ltd. announced that its associate company Altamira Medica has obtained marketing approval from the National Medical Products Administration (NMPA) of China for its Bentrio nasal spray in allergic rhinitis. The clearance will allow Nuance Pharma, Medica’s licensee and distribution partner, to start marketing and distributing Bentrio in Mainland China. According to epidemiological studies, nearly 200 million people in China are estimated to be affected by allergic rhinitis, and prevalence keeps increasing. 

“We are very excited by the regulatory clearance of Bentrio for China, which is one of the world’s largest markets for ‘over the counter’ consumer health products,” commented Thomas Meyer, Medica’s Chairman and CEO. “Thanks to its triple mode of action, which does not require any drug ingredient for protecting against airborne allergens, and its preservative-free formulation, Bentrio has demonstrated strong efficacy and good tolerability across several allergic rhinitis trials. We look forward to supporting the launch of the product in China by our esteemed partner Nuance Pharma, which has built a strong and growing franchise in consumer health and in respiratory diseases.”

“The regulatory approval of Bentrio represents an important milestone for Nuance Pharma’s effort in the allergy space” commented Mark G. Lotter, CEO and Founder of Nuance Pharma. “Building upon Nuance’s existing efforts on Bentrio in the region and commercial capabilities in China, we are excited to broaden the access of Bentrio to benefit the allergic rhinitis patients in China.”